Affinity DataIC50: 2.80nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 7.30nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 7.30nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 10.4nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 10.8nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 11.7nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 11.7nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 14.4nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 15.3nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 16.3nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 16.4nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 17.2nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 17.3nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 18.1nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 18.1nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 19.1nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 19.5nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 20.6nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 20.8nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 24.6nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 26.3nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 26.5nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 29.2nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 29.3nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 31.8nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 39.4nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 61.9nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair
Affinity DataIC50: 115nMAssay Description:PBMCs from healthy subjects are separated from whole blood using a density gradient (Lymphoprep, Axis-Shield Healthcare). Cells are added to a 96 wel...More data for this Ligand-Target Pair